Navigation Links
Monogram Announces First Medicare Payment for Trofile(TM)
Date:9/24/2007

Medicare to Pay for Trofile at Monogram's List Price

SOUTH SAN FRANCISCO, Calif., Sept. 24 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that the first Medicare payment for its Trofile Assay has been processed, at an amount equal to Monogram's list price, by the National Heritage Insurance Company (NHIC), the contractor that administers Medicare programs in California.

NHIC had previously established coding guidance for Trofile. For patients throughout the U.S., Medicare claims for Trofile are submitted to NHIC, which is the local Medicare part B Contractor in California, where Trofile tests are performed. NHIC's coding guidance for healthcare providers references the need for tropism testing as indicated in the FDA labeling for maraviroc, and acknowledges that Monogram's Trofile Assay was the test for tropism on which the FDA clinical trials of Selzentry (maraviroc) were based.

Monogram's Trofile Assay is the only clinically validated assay for assessing tropism of patients, is the only assay that has been used in phase II and phase III clinical trials of CCR5 antagonists, and has been used in all such clinical trials to date.

"Providing this reimbursement for Trofile is an important acknowledgement by Medicare of the value of Trofile as a tool for guiding the use of Selzentry," said William D. Young, Monogram CEO. "We are making good progress in our discussions with other public and private payers with regard to reimbursement for Trofile and, to date, we have submitted claims to 15 separate payers. We are encouraged by the initial adoption of Trofile by physicians."

About Trofile

Trofile is a patient selection co-receptor tropism assa
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Monogram Presents Results of First ETag Breast Cancer Studies
2. PM announces a new health care order for India
3. Ramdoss Announces Introduction of RCH-II
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
6. Tibet Announces the Dalai Lama’s Tour of South Americ
7. NHS announces further Cost cutting Measures
8. Indian PM Announces Of Setting Up India Study Center At Tashkent
9. PowderMed Announces Needle-Less Flu Vaccine
10. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
11. Australian Government Announces Survey To Tackle Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast 13452 1Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast 13452 2More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 1More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 2More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 3More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 4More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 53936 5Sanofi Pasteur Submits Supplemental Application for A 28H1N1 29 Pandemic Vaccine to U S FDA 4835 1Sanofi Pasteur Submits Supplemental Application for A 28H1N1 29 Pandemic Vaccine to U S FDA 4835 2Sanofi Pasteur Submits Supplemental Application for A 28H1N1 29 Pandemic Vaccine to U S FDA 4835 3